RenovoRx Inc. provided an update on its recent commercialization efforts and clinical progress. The company reported approximately $900,000 in revenue through the third quarter of 2025 following the initiation of commercial activities for its FDA-cleared RenovoCath® device. As of January 2026, the number of cancer center customers approved to purchase RenovoCath increased from 5 to 14, with 9 active commercial users and additional centers in the approval process. RenovoRx estimates an initial potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device, with potential for further expansion in future applications. The company continues to develop combination therapies based on its proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform, including a lead drug-device candidate, Intra-Arterial Gemcitabine $(IAG)$, which has received FDA Orphan Drug Designation for pancreatic and bile duct cancers. RenovoRx is advancing its pivotal Phase III TIGeR-PaC study for the treatment of locally advanced pancreatic cancer, with enrollment completion expected in the first half of 2026 and final data anticipated in 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on February 02, 2026, and is solely responsible for the information contained therein.